Skip to main content
Erschienen in: Cancer Causes & Control 4/2006

01.05.2006 | Special Section on Cancer and Rhythm

Does Incidence of Breast Cancer and Prostate Cancer Decrease with Increasing Degree of Visual Impairment

verfasst von: Eero Pukkala, Matti Ojamo, Sirkka-Liisa Rudanko, Richard G. Stevens, Pia K. Verkasalo

Erschienen in: Cancer Causes & Control | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Objective

The issue of light at night and cancer continuously attracts discussion. The major hypotheses are that melatonin may decrease risk of hormone-related cancers, particularly breast cancer, or even act as a potent antioxidant and thus have a protective effect against cancer development in general.

Methods

We tested the hypothesis that blind persons are at lower risk of cancer in a follow-up study linking a cohort of 17,557 persons with visual impairment identified from the Finnish Register of Visual Impairment with cancer incidence data of the Finnish Cancer Registry for years 1983–2003.

Results

Breast cancer risk in females decreased by degree of visual impairment, and a similar but less consistent trend was observed for prostate cancer in males. The incidence for the remaining cancers among nearly to totally blind persons was significantly higher than in average Finnish population.

Conclusions

Our findings add to the suggestive epidemiological evidence for a decreased risk of hormone-related cancers in people with visual impairment and, consequently, a relationship between visible light at night and breast cancer risk. The result is strongly against the hypothesis of a systemic protective effect related lack of visible light.
Literatur
1.
Zurück zum Zitat Stevens RG (1987) Electric power use and breast cancer: a hypothesis. Am J Epidemiol 25:556–561 Stevens RG (1987) Electric power use and breast cancer: a hypothesis. Am J Epidemiol 25:556–561
2.
Zurück zum Zitat Hahn RA (1991) Profound bilateral blindness and the incidence of breast cancer. Epidemiology 2:208–210PubMed Hahn RA (1991) Profound bilateral blindness and the incidence of breast cancer. Epidemiology 2:208–210PubMed
3.
Zurück zum Zitat Feychting M, Österlund B, Ahlbom A (1998) Reduced cancer incidence among the blind. Epidemiology 9:490–494PubMed Feychting M, Österlund B, Ahlbom A (1998) Reduced cancer incidence among the blind. Epidemiology 9:490–494PubMed
4.
Zurück zum Zitat Reiter RJ, Melcheorri D, Sewerynek E, et al. (1995) A review of the evidence supporting melatonin’s role as an antioxidant. J Pineal Res 18:1–11PubMed Reiter RJ, Melcheorri D, Sewerynek E, et al. (1995) A review of the evidence supporting melatonin’s role as an antioxidant. J Pineal Res 18:1–11PubMed
5.
Zurück zum Zitat Pukkala E, Verkasalo PK, Ojamo M, Rudanko S-L (1999) Visual impairment and cancer:a population-based cohort study in Finland. Cancer Causes Control 10:13–20CrossRefPubMed Pukkala E, Verkasalo PK, Ojamo M, Rudanko S-L (1999) Visual impairment and cancer:a population-based cohort study in Finland. Cancer Causes Control 10:13–20CrossRefPubMed
6.
Zurück zum Zitat Verkasalo PK, Pukkala E, Stevens RG, Ojamo M, Rudanko S-L (1999) Inverse association between breast cancer incidence and degree of visual impairment in Finland. Brit J Cancer 80:1459–1460PubMed Verkasalo PK, Pukkala E, Stevens RG, Ojamo M, Rudanko S-L (1999) Inverse association between breast cancer incidence and degree of visual impairment in Finland. Brit J Cancer 80:1459–1460PubMed
7.
Zurück zum Zitat Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 33:365–369PubMed Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 33:365–369PubMed
8.
Zurück zum Zitat Pukkala E (1992) Use of record linkage in small-area studies. In: Elliot P, Guzick J, English D, Stern R (eds) Geographical and Environmental Epidemiology. Oxford University Press, Oxford, pp 125–131 Pukkala E (1992) Use of record linkage in small-area studies. In: Elliot P, Guzick J, English D, Stern R (eds) Geographical and Environmental Epidemiology. Oxford University Press, Oxford, pp 125–131
9.
Zurück zum Zitat Kliukiene J, Tynes T, Andersen A (2001) Risk of breast cancer among Norwegian women with visual impairment. Brit J Cancer 84:397–399PubMed Kliukiene J, Tynes T, Andersen A (2001) Risk of breast cancer among Norwegian women with visual impairment. Brit J Cancer 84:397–399PubMed
10.
Zurück zum Zitat Henderson BE, Pike MC, Bernstein L, et al. (1996) Breast cancer. In: Schottenfeld D, Fraumeni JFJ (eds) Cancer Epidemiology and Prevention 2nd edn. Oxford University Press, New York, pp 1022–1039 Henderson BE, Pike MC, Bernstein L, et al. (1996) Breast cancer. In: Schottenfeld D, Fraumeni JFJ (eds) Cancer Epidemiology and Prevention 2nd edn. Oxford University Press, New York, pp 1022–1039
11.
Zurück zum Zitat Hartikainen R, Kuoppala T, Ojamo M (1998) Elintapoja muisteltiin tutkijoiden hyödyksi [Life style of the visually impaired] [In Finnish] Airut 87:872–873 Hartikainen R, Kuoppala T, Ojamo M (1998) Elintapoja muisteltiin tutkijoiden hyödyksi [Life style of the visually impaired] [In Finnish] Airut 87:872–873
12.
Zurück zum Zitat Blask DE, Pelletier DB, Hill SM, et al. (1991) Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo. J Cancer Res Clin Oncol 117:526–532CrossRefPubMed Blask DE, Pelletier DB, Hill SM, et al. (1991) Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo. J Cancer Res Clin Oncol 117:526–532CrossRefPubMed
13.
Zurück zum Zitat Baldwin WS, Barret JC (1998) Melatonin:receptor-mediated events that may affect breat and other steroid hormone dependent cancers. Mol Carcinogen 21:149–155 Baldwin WS, Barret JC (1998) Melatonin:receptor-mediated events that may affect breat and other steroid hormone dependent cancers. Mol Carcinogen 21:149–155
14.
Zurück zum Zitat Pukkala E, Aspholm R, Auvinen A, et al. (2003) Cancer incidence among 10,211 airline pilots:A Nordic study Aviat Space Environ Med 74:699–706PubMed Pukkala E, Aspholm R, Auvinen A, et al. (2003) Cancer incidence among 10,211 airline pilots:A Nordic study Aviat Space Environ Med 74:699–706PubMed
Metadaten
Titel
Does Incidence of Breast Cancer and Prostate Cancer Decrease with Increasing Degree of Visual Impairment
verfasst von
Eero Pukkala
Matti Ojamo
Sirkka-Liisa Rudanko
Richard G. Stevens
Pia K. Verkasalo
Publikationsdatum
01.05.2006
Verlag
Kluwer Academic Publishers
Erschienen in
Cancer Causes & Control / Ausgabe 4/2006
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-005-9005-6

Weitere Artikel der Ausgabe 4/2006

Cancer Causes & Control 4/2006 Zur Ausgabe

Special Section on Cancer and Rhythm

Tumor Suppression by the Mammalian Period Genes

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.